Navigation Links
Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--May 21, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notes the publication of new clinical data relevant to the development strategy for Ceflatonin(R) (homoharringtonine). The paper "Targeted therapy and the T315I mutation in Philadelphia-positive leukemias" by researchers Simona Soverini and colleagues at the University of Bologna, Italy (Haematologica Volume 92, pages 401-404) offers insight into the growing therapeutic challenge presented by the T315I Bcr-Abl point mutation in patients with chronic myeloid leukemia (CML). The T315I Bcr-Abl mutation is associated with the development of resistance to tyrosine kinase inhibitor drugs such as imatinib (Gleevec(R)).

The paper describes the clinical progress of Gleevec-resistant CML patients who were treated with dasatinib (Sprycel(R)).

Key points of the publication are as follows:

-- The study followed 45 Philadelphia-positive CML and acute lymphoblastic leukemia (ALL) patients who had failed Gleevec, and who were migrated to dasatinib therapy.

-- Eight of the 45 patients (17.7%) had primary resistance to dasatinib, and showed no response. Seven of these 8 patients harboured the T315I point mutation.

-- A further 13 patients (28.8%) acquired resistance to dasatinib after a median of 7 months, and seven (15.6%) of these patients were T315I positive.

-- In summary the T315I mutation was associated with resistance to dasatinib in 31% of patients, and the total number of patients who were resistant to therapy was 46.7%.

-- This incidence of T315I-associated resistance is higher than has previously been reported and reflects, in the words of Soverini et al., that the T315I mutation "is likely to become the prevalent mutation in those who fail to benefit from second-line treatment with dasatinib".

Data from this publication support ChemGenex's t
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
Post Your Comments:
(Date:7/28/2014)... Calif. , July 28, 2014 ... leader in lifestyle healthcare and subsidiary ... that it has acquired Physician Recommended Nutriceuticals (PRN) ... omega-3s, and related products for dry ... Plymouth Meeting, PA, in a transaction worth up ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
Breaking Medicine Technology:ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... Delaware, October 10, 2011 As the ... gigabytes of health and health-related technology information, and the ... providers are going to adopt new patterns to successfully ... reimbursement processes. In order to cope with ...
... Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) ... strategic collaboration for the development, commercialization and supply of ... AKP,s formulation of human parathyroid hormone (human PTH 1-34), ... risk of fracture.  Under the terms ...
Cached Medicine Technology:MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 2MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 3MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 4Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 2Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 3Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 4
(Date:7/29/2014)... Seattle, Wa (PRWEB) July 29, 2014 Gout ... standards of lifestyles have proven that last statement essentially ... However, what many people still do not have are the ... not only is it costly to maintain treatment for it, ... hamper one’s daily activities to a grinding halt. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Consilium Staffing, Your ... year-over-year at the halfway point of 2014, with strong indications ... the second half of this year. , “This is a ... Vice President of Consilium Staffing. , “We are proud ... the year, but we are even more excited about how ...
(Date:7/29/2014)... Guests at Napa Valley's quintessential luxury resort, ... sleep experience. The top of each luxurious resort bed is ... These expertly crafted, 100% Egyptian cotton white duvets and pillow ... upon closer look, words are woven in the linens that ... , Intentional breathing and visualization are keys to ...
(Date:7/29/2014)... 29, 2014 A Forever Recovery , ... off to a great start and gives them a solid ... sponsor of the National Cherry Festival kickoff concert held on ... which was co-sponsored by Miller Lite and in partnership with ... Pepsi Bay Side Music Stage presented by Blue Cross Blue ...
(Date:7/29/2014)... Recently, Stwd.co.uk, a distinguished online supplier of special ... dresses . As a summer special offer, all these new ... percent off. All new and old customers can enjoy the ... to announce the new evening outfits. They want to bring ... happy to launch the big sale. Our cheap evening dresses ...
Breaking Medicine News(10 mins):Health News:Gout Natural Remedy Report Review | The Ultimate Secret to Eliminating Gout Naturally – Vinamy.com 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:A Forever Recovery Sponsors National Cherry Festival Kickoff Concert Featuring Collective Soul on July 5 in Traverse City, MI 2Health News:Cheap Prom Dresses Available At Popular Online Store Stwd.co.uk 2
... ... , ... 22, 2010 -- DonJoy Velocity ankle braces were the best selling ankle brace ... ankle braces were double that of other ankle supports sold on the site., , , ...
... finds people are more likely to strike forefoot first, easing impact ... $100 on a fancy pair of running shoes, this news may ... for your body because of the way your feet land on ... course. Even so, "the way barefoot runners use their feet and ...
... ... months, numerous prominent politicians along with TV stars and sports heroes have made headline ... supporters cannot seem to get enough of the tawdry details of the betrayers, the ... lives. The true heroes are left standing in the shadows of their betrayers. ...
... , CALIFANO CONTINUES AS CHAIRMAN , ... Addiction and Substance Abuse (CASA) at Columbia University announced today ... Edmund S. Muskie School of Public Service, will become President ... succeeding Joseph A. Califano, Jr. , the former U.S. Secretary of ...
... , , NEW YORK , Jan. 27 ... $250,000 grant to the Clinton Health Access Initiative (CHAI), a ... in 2002. The grant will ensure the continuation of HIV/AIDS ... of the devastating January 12 earthquake. , ...
... or the woman who suggests using a condom makes no ... the woman suggests it makes a difference. If she highlights ... an erotic and fun activity, other women judge her more ... a condom or shares her concerns about sexually transmitted infections. ...
Cached Medicine News:Health News:DonJoy Velocity Ankle Brace is the Best Selling Ankle Brace in 2009 2Health News:Barefoot Best for Running? 2Health News:Barefoot Best for Running? 3Health News:The True Hero Stands in the Shadow of the Betrayer 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 3Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 4Health News:Ford Foundation Commits $250,000 to Support HIV/AIDS Services in Haiti 2Health News:Condom or no condom? It's not what you say, it's how you say it 2
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... full-featured healthcare bed system providing a comfortable, ... management of larger patients, ,INDICATIONS: ,Large ... patients at risk for pressure ulcers, ... lbs. (including accessories), ,PRECAUTION: ,Side Rails ...
... beds feature folding head end and foot end deck ... head end and foot end deck panels folded the ... 67". This compact length makes storage, delivery and pick ... is not available on Model 4748B, Basic Maxi Rest ...
Medicine Products: